61/100BGenmab A stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Genmab A/S ADS is 50.83, 1.0% below the current price of 51.37. Their targets range from 40.00 to 70.00.
Of the 6 firms that rated Genmab A/S ADS in the past 12 months, 5 rate it buy or strong buy, 1 hold and 0 sell or strong sell (each firm at its latest rating): a Strong buy consensus.
Analysts' 1-year price targets range from 40.00 to 70.00, with an average of 50.83.
| Buy | 5 | |
| Hold | 1 | |
| Sell | 0 |
12-month price target
| Highest target | 70.00 |
| Average target | 50.83 |
| Lowest target | 40.00 |
| Current price | 51.37 |
Genmab A price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Genmab A/S ADS price target and rating?
How analysts rate Genmab A, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
5 of 6 firms rate it buy now, against 5 of 5 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Genmab A analyst upgrades, downgrades and price targets
The latest rating change came on 26 October 2026, when JP Morgan upgraded Genmab A/S ADS from Neutral to Overweight. The most recent new target came from H.C. Wainwright on 29 October 2026: 70.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 29 Oct 2026 | H.C. Wainwright | — | 38.00 → 70.00 | +84.2% | 57.29 |
| 26 Oct 2026 | TD Cowen Yaron Werber | Reiterated · Buy | 52.00 | — | 44.69 |
| 26 Oct 2026 | JP Morgan | Upgraded · Neutral → Overweight | — | — | — |
| 20 Oct 2026 | Morgan Stanley Sean Laaman | — | 42.00 | — | 38.50 |
| 7 Oct 2026 | Guggenheim Michael Schmidt | Reiterated · Buy | 54.00 → 58.00 | +7.4% | 37.80 |
| 5 Oct 2026 | Guggenheim Michael Schmidt | Reiterated · Buy | 40.00 → 54.00 | +35.0% | 34.75 |
| 22 Jul 2026 | New Street | — | 43.00 | — | 28.37 |
| 22 Jul 2026 | TD Cowen | Upgraded · Hold → Buy | — | — | — |
| 27 May 2026 | Truist Financial Gregory Renza | — | 48.00 → 40.00 | -16.7% | 26.89 |
| 30 Apr 2026 | H.C. Wainwright | — | 39.00 → 38.00 | -2.6% | 26.11 |
| 26 Mar 2026 | Wolfe Research | — | 32.00 | — | 26.03 |
| 23 Feb 2026 | Guggenheim Michael Schmidt | Reiterated · Buy | 43.00 → 40.00 | -7.0% | 29.29 |
| 17 Feb 2026 | Jefferies Benjamin Jackson | — | 41.50 | — | 30.03 |
| 20 Jan 2026 | H.C. Wainwright | — | 40.00 → 39.00 | -2.5% | 32.25 |
Genmab A EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect Genmab A/S ADS's EPS to grow 20.6% a year until 2028. Over the last 5 years it fell 26.6% a year, and over the last 3 years it fell 42.9%.
Analysts expect Genmab A/S ADS's revenue to grow 22.8% a year until 2028. Over the last 5 years it fell 18.1% a year, and over the last 3 years it fell 36.4%.
Revenue
EPS
Does Genmab A beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 37.2% off the result, either way, and their revenue estimate 2.3%, over the last 12 quarters.
- EPS beats
- 11 / 30
- Revenue beats
- 19 / 30
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +8.5%
- Since
- August 2019
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 5 Nov 2026 | 0.36 | 0.56 | +55.6% | 1.20B | 1.19B | -0.9% |
| Q2 FY2026 | 6 Aug 2026 | 0.37 | 0.54 | +45.9% | 1.12B | 1.16B | +3.5% |
| Q1 FY2026 | 7 May 2026 | 0.15 | 0.09 | -42.0% | 905.77M | 896.00M | -1.1% |
| Q4 FY2025 | 17 Feb 2026 | 0.46 | 0.05 | -89.1% | 1.07B | 1.06B | -0.8% |
| Q3 FY2025 | 6 Nov 2025 | 0.48 | 0.65 | +35.4% | 1.01B | 1.02B | +1.1% |
| Q2 FY2025 | 7 Aug 2025 | 0.39 | 0.54 | +38.5% | 952.56M | 924.81M | -2.9% |
| Q1 FY2025 | 8 May 2025 | 0.23 | 0.31 | +34.8% | 755.47M | 725.99M | -3.9% |
| Q4 FY2024 | 12 Feb 2025 | 0.36 | 0.57 | +58.3% | 894.71M | 895.80M | +0.1% |
| Q3 FY2024 | 6 Nov 2024 | 0.35 | 0.29 | -17.1% | 809.62M | 815.16M | +0.7% |
| Q2 FY2024 | 8 Aug 2024 | 0.29 | 0.22 | -24.1% | 732.47M | 789.59M | +7.8% |
| Q1 FY2024 | 2 May 2024 | 0.16 | 0.16 | 0.0% | 572.03M | 598.08M | +4.6% |
| Q4 FY2023 | 14 Feb 2024 | 0.34 | 0.36 | +5.9% | 671.21M | 675.34M | +0.6% |
Genmab A stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Genmab A/S ADS's earnings grow at the 20.3% a year analysts expect to FY2028, then 15.0% a year, it would earn about 3.57 a share in FY2030. At the P/E it has traded at over the last five years (12.4 to 57.2) that is 44.25 to 204.40 a share, or 119.46 at its average P/E of 33.4. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 1.25 | 15.47 | 41.76 | 71.45 |
| FY2027 | 1.63 | 20.14 | 54.36 | 93.01 |
| FY2028 | 2.70 | 33.46 | 90.33 | 154.55 |
| FY2029 (extrapolated) | 3.11 | 38.48 | 103.88 | 177.74 |
| FY2030 (extrapolated) | 3.57 | 44.25 | 119.46 | 204.40 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 15.0% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (12.4, 33.4, 57.2).
Is Genmab A stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
Genmab A/S ADS's P/E of 43.3 is near the top of its 5-year range (2.3 to 47.0, median 4.8). Analysts expect faster growth than in recent years, which can explain part of the high P/E. Fair value is not a reliable guide for Genmab A/S ADS: its earnings swing (EPS fell 87.3% in FY2025), so its usual P/E would mislead. Its forward P/E, on the consensus for FY2026, is 41.1.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 43.27
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 4.81
- Five-year P/E range
- 2.3 – 47.0
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 41.13
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 2.13
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- -1.0%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 35.760 | 71.4258Price 35.76193 | +99.7% | |
| 29.080 | 56.2434Price 29.0896 | +93.4% | |
| 240.360 | 464.26205Price 240.36627 | +93.2% | |
| 202.040 | 384.58163Price 202.042,644 | +90.3% | |
| 161.340 | 305.52160Price 161.34396 | +89.4% | |
| 125.395 | 237.44178Price 125.40297 | +89.4% | |
| 159.580 | 300.48225Price 159.58376 | +88.3% |
Furthest below the fair value on each stock's page, updated every day.